Information Provided By:
Fly News Breaks for November 14, 2019
Nov 14, 2019 | 08:10 EDT
JPMorgan analyst Doug Anmuth downgraded Cardlytics to Neutral from Overweight with an unchanged price target of $58. The analyst cites valuation for the downgrade following the stock's 43% day-after-earnings appreciation on Wednesday. Cardlytics shares are up 426% year-to-date, Anmuth tells investors in a research note. Despite the downgrade, his fundamental view on the company remains positive. He still believes Cardlytics is "uniquely positioned" to leverage purchase data from more than 2,000 financial institutions.
News For CDLX From the Last 2 Days
Apr 15, 2021 | 06:45 EDT
Wells Fargo analyst Timothy Willi upgraded Cardlytics to Overweight from Equal Weight with a $150 price target. Willi believes the recent underperformance has created a favorable entry point for shares, and sees several fundamental catalysts over the near to medium term, the analyst tells investors in a research note. The analyst views the risk/reward as favorable at current levels and the liquidity position as stable.